About
Physician-scientist with cross-disciplinary expertise in clinical development, R&D, and…
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
Northwestern University
-
Activities and Societies: Member, Society for Neuroscience, 2006- Member, American Association for Advancement of Science (AAAS), 2009- Member, Nature Network, 2008-
- University Fellow
- Teaching Assistant
- Research Assistant
- Touch perception: a combination of in vivo electro-physiology, computational modeling and mechanical instrumentation.
- Developed and implemented algorithms to analyze data from in vivo neural recordings.
- Research applications to haptic devices, medical device signal processing and instrumentation.
- Taught undergraduate classes in physiology and neurobiology. Kept abreast of current developments in…- University Fellow
- Teaching Assistant
- Research Assistant
- Touch perception: a combination of in vivo electro-physiology, computational modeling and mechanical instrumentation.
- Developed and implemented algorithms to analyze data from in vivo neural recordings.
- Research applications to haptic devices, medical device signal processing and instrumentation.
- Taught undergraduate classes in physiology and neurobiology. Kept abreast of current developments in immunology, neurology, metabolic disorders, cancer for teaching related activities. -
-
- Institute Fellow
- Teaching Fellow
- Ranked 2nd in Class-
- Ranked in top 0.1% candidates in Graduate Aptitude Test
- Developed mathematical and computational models of neurons in areas of brain involved in learning and memory.
- Taught classes in electro-physiology, teaching both basic physical principles and clinical applications of electro-phyiological tools.
- Extensive course-work in applied mathematics, modeling and simulation, statistics and signal processing…- Institute Fellow
- Teaching Fellow
- Ranked 2nd in Class-
- Ranked in top 0.1% candidates in Graduate Aptitude Test
- Developed mathematical and computational models of neurons in areas of brain involved in learning and memory.
- Taught classes in electro-physiology, teaching both basic physical principles and clinical applications of electro-phyiological tools.
- Extensive course-work in applied mathematics, modeling and simulation, statistics and signal processing.
- Research applicable to understanding the effects of drugs on learning and memory and to potential targets for therapeutics. -
Top 0.1% candidates Medical Entrance Examination
Top 0.1% Candidates, all years of medical education
Winner of Paranjape Memorial Pharmacology Quiz, Seth GS Medical College and King Edward Memorial Hospital, University of Mumbai
Winner of numerous medical quizzes at Grant Medical College, Mumbai
Other similar profiles
Explore more posts
-
Scott Gottlieb
I'm delighted to share news of this new AI-focused drug discovery company, Xaira, built on foundational technology from David Baker and led by Marc Tessier-Lavigne. The company applies AI tools to unlock opportunities in drug discovery for aspects of biology that we believe are not readily obtainable with conventional methods. I co-led NEA's investment in Xaira, along with my NEA partner and the firm’s co-CEO Mohamad Makhzoumi, and I will be joining Xaira’s board. Our enthusiasm for Xaira based on our belief that applying AI and large language models to biology holds immense promise and is still in its early stages. Currently, the application of AI to biology relies on model architectures borrowed from the tech world. A lack of well-curated clinical training sets hinders building and training these models effectively. This limits the advancement of AI in solving biological problems compared to other fields. Xaira aims to bridge this gap. We now have a clear understanding of the data needed to answer fundamental biological questions. By iterating on leading life science models and using focused perturbation data generated through our large-scale experiments, Xaira will generate data specifically suited to building advanced model architectures that are optimized for biology -- and hopefully, unlock therapeutic opportunities for patients who are not being optimally served by existing therapeutics.
13 Comments -
Carl Schoellhammer
Investment, therapeutic viability, and next-gen. technologies... That's what the cell therapy field needs. I had the pleasure of sitting down with Jason C. Foster of Ori Biotech recently on their podcast to talk all things cell therapy, the enabling technologies that support this modality, and the need for more investment. What did we touch on (and link to full podcast below)? Investors needing to see a return when investing in cell therapies. Need to bring manufacturing costs down to expand access. Next-gen. tools to create better, more robust therapies. Purpose-built therapies require purpose-built tools! Our consulting practice, how we help our clients, and how we view the field of advanced therapies. We take a differentiated approach to tracking, following, and mapping key trends across advanced therapies to bring novel, business-impacting insights to our clients. Want to discuss any of the above? Where the field of cell therapies are going? What it means for your own development pipeline? Reach out and let me know what you think in the comments! #celltherapy #venturecapital #consulting https://lnkd.in/g7SH9FAU
3 Comments -
Carl Schoellhammer
When investors think your gene therapy isn't good enough... That's what Lexeo is feeling right now on LX2006 for cardiomyopathy associated with Friedreich's Ataxia. Their Ph1/2 trial saw 50% of patients (8 total in the trial) experience a reduction of 10% in left ventricular mass index. There are only a handful of companies developing therapies for Friedreich's Ataxia, let alone the heart-related components of this rare disease. While Lexeo was optimistic about the data and taking it to discuss a future pivotal study with regulators, the market was not, knocking the stock down at present ~25%. The public markets are brutal with earlier stage companies. Depending on capital needs, it can be a bit easier to not be public when you're early in development. Regardless, another piece of positive news for AAV as it slowly comes out of its winter. Lines up with our beginning of the year predictions below! https://lnkd.in/drRreSCd
2 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More